MARKET

MRSN

MRSN

Mersana
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.08
+0.14
+0.68%
After Hours: 20.05 -0.03 -0.15% 17:38 06/05 EDT
OPEN
20.30
PREV CLOSE
19.95
HIGH
21.78
LOW
19.95
VOLUME
1.20M
TURNOVER
--
52 WEEK HIGH
23.40
52 WEEK LOW
1.320
MARKET CAP
1.18B
P/E (TTM)
-14.3377
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MRSN stock price target is 21.40 with a high estimate of 26.00 and a low estimate of 19.00.

EPS

MRSN News

More
Why Mersana Therapeutics (MRSN) Could Be Positioned for a Surge
Zacks · 2d ago
Stoke Therapeutics Appoints Julie Anne Smith to its Board of Directors
Business Wire · 2d ago
Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Mersana Therapeutics, Inc., (MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the closing of its underwri
GlobeNewswire · 3d ago
The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics
Zacks · 4d ago
5 Top Stocks Up 100%+ in May With More Room to Run
Zacks · 5d ago
72 Biggest Movers From Friday
Gainers Adaptimmune Therapeutics plc (NASDAQ: ADAP) shares jumped 127.8% to close at $11.07 on Friday after the company announced updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology Annual Meeting.
Benzinga · 5d ago
Notable Insider Buys: Avis, Dynavax And Formula One
Insider buying can be an encouraging signal for potential investors.Beneficial owner Berkshire Hathaway made a huge purchase last week.A director took advantage of a coronavirus vaccine contender's secondary offering.
Benzinga · 6d ago
Mersana Therapeutics (MRSN) Presents XMT-1536 Interim Expansion Data from Phase 1 Study - Slideshow
Seeking Alpha - Article · 05/29 17:42

Industry

Biotechnology & Medical Research
-0.15%
Pharmaceuticals & Medical Research
+0.37%

Hot Stocks

Symbol
Price
%Change

About MRSN

Mersana Therapeutics, Inc. is a biotechnology company. The Company is focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies.
More

Webull offers kinds of Mersana Therapeutics Inc stock information, including NASDAQ:MRSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRSN stock news, and many more online research tools to help you make informed decisions.